Sydney Tang Hong KongHong Kong, China

Wcn26 Post edited Speaker Card

Time	Session

3:45 p.m. 4:45 p.m.	HIT! High Impact Clinical Trials 1 Sydney Tang Chair Hong Kong, China Remodel Overview - Framework And Key Outcomes PetterBjornstad Speaker United States Semaglutide Improves Kidney Outcomes Regardless Of SGLT2i Use In People With Chronic Kidney Disease And Type 2 Diabetes: Post-hoc Analysis The Remodel Trial DavidCherney Speaker Canada ACHIEVE B-cell Targeted Therapy for Idiopathic Nephrotic Syndrome: Results of the Phase III Global Multicenter Inshore Trial Evaluating Efficacy and Safety of Obinutuzumab vs Mycophenolate Mofetil JulienHogan Speaker France Main Hall

Time

Session

3:45 p.m.

4:45 p.m.

HIT! High Impact Clinical Trials 1

Sydney Tang Chair Hong Kong, China

Main Hall

Time	Session

2:10 p.m. 3:10 p.m.	HIT! High Impact Clinical Trials 3 - In IgA Nephropathy Sydney Tang Chair Hong Kong, China EFFICACY AND SAFETY RESULTS OF ATRASENTAN IN PATIENTS WITH IGA NEPHROPATHY ON SODIUM‚ÄÌGLUCOSE CO-TRANSPORTER 2 INHIBITORS: PHASE II, RANDOMIZED, PLACEBO-CONTROLLED, CROSSOVER TRIAL (ASSIST) HiddoLambers Heerspink Speaker Netherlands EFFICACY AND SAFETY OF A TARGETED-RELEASE FORMULATION OF BUDESONIDE (HR19042 CAPSULES) IN PATIENTS WITH PRIMARY IGA NEPHROPATHY: A RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED PHASE 2/3 TRIAL XiaobingYang Speaker China EVALUATING THE EFFECT OF SPARSENTAN VS IRBESARTAN ON URINE INFLAMMATORY AND PROFIBROTIC BIOMARKERS IN THE PHASE 3 PROTECT TRIAL OF PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IGA NEPHROPATHY (IGAN): FINAL 24-MONTH RESULTS FROM THE PHASE III APPLAUSE-IGAN STUDY VladoPerkovic Speaker Australia Main Hall

Time

Session

2:10 p.m.

3:10 p.m.

HIT! High Impact Clinical Trials 3 - In IgA Nephropathy

Sydney Tang Chair Hong Kong, China

Main Hall